1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68998FEAA886C54B90025874100443414
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-more-effective-medical-affairs-product-launch-teams
18
19
2098.80.143.34
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Building More Effective Medical Affairs Product Launch Teams

ID: POP-342


Features:

14 Info Graphics

31 Data Graphics

650+ Metrics


Pages: 57


Published: 2021


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Savvy Medical Affairs groups are increasingly taking center stage in launch preparations for new products. This seismic shift in the healthcare industry has seen organizations implementing medical support and engagement strategies earlier in the product lifecycle across a growing range of high-impact programs in concert with a burgeoning number of internal and external stakeholders.

Best Practices, LLC conducted this benchmarking research to explore Medical Affairs’ growing role in product launch. The report probes evolving roles and responsibilities, cross-functional alignment, performance metrics, resourcing, activities effectiveness, launch timeline, and digital launch tools deployment. In addition, this report examines the most critical success factors and challenges to Medical Affairs’ success in achieving best-in-class launch preparedness.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Biotech; Diagnostic; Health Care; Chemical; Consulting; Communications; Consumer Products; Clinical Research; Laboratories; Science


Companies Profiled:
Adamas Pharmaceuticals; Albireo; Alcon; Apellis Pharmaceuticals; ASC Therapeutics; AstraZeneca; Baxter Healthcare; BELLUS Health; BIAL; bioMerieux; Boehringer Ingelheim; Cardinal Health; Cipla; Eisai; EMD Serono; Eurofarma; Fidia Pharma USA Inc.; Gedeon Richter ; Genentech; GlaxoSmithKline ; GW Pharmaceuticals; Helsinn; Ipsen; Karyopharm Therapeutics; Kyowa Kirin; Labaid Group; Lundbeck; Matinas BioPharma; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck KGaA; NexGen Healthcare Communications; Novartis; Pfizer; Pixacore; Sanofi; Sandoz; Santen; Sunovion; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies; Thermo Fisher Scientific; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 60 executives from 43 leading life sciences companies in this research through a benchmark protocol. The study insights are drawn primarily from directors and upper management executives, representing nearly 80% of the participants.

Key topics covered in this report include:

  • Medical Leadership Roles and Activity Effectiveness
  • Ensuring Cross-functional Alignment and Collaboration
  • Medical Launch Evolution
  • Launch Activities Timeline, Performance Tracking and Resourcing
  • Critical Success Factors and Major Pitfalls for Medical Affairs During Launch
  • Digital Launch Implementation and Impact

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Launch Tool Deployment: Benchmark participants typically kick off digital activities one phase later than when they should ideally start, according to their own standards. The widest gap occurs in actual HEOR engagement time vs. ideal.

  • Digital Implementation: Digital implementation is accelerating with the use of social platform tools, education programs and virtual advisory boards. These tools are predominantly deployed at launch or 12 months prior.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 4
II.
Section I: Launch Excellence and Medical’s Role & Activity EffectivenessPg. 6-12
III.
Section II: Ensuring Cross-functional Alignment and CollaborationPg. 13-15
IV.
Section III: Adopting to Ongoing Changes in Medical LandscapePg. 16-20
V.
Section IV: Launch Timeline, Preparedness Metrics and ResourcingPg. 21-26
VI.
Section V: Critical Success Factors and Major PitfallsPg. 27-32
VII.
Section VI: Digital Influence on Launch Processes and Launch Tool DeploymentPg. 33-41
VIII.
Section VII: Participant DemographicsPg. 42-44
IX.
Section VIII: Detailed Benchmark Study DataPg. 45-56
X.
Section IX: About Best Practices, LLCPg. 57

    List of Charts & Exhibits

    I: Launch Excellence and Medical’s Role & Activity Effectiveness

    • Medical launch excellence framework
    • Medical Affairs’ role at launch
    • Medical leadership roles at launch
    • Effectiveness of Medical Affairs organization in regard to different activities for a successful launch
    • Most effective launch activities for Medical Affairs
    • Improvement opportunities for Medical Affairs around launch activities

    II: Ensuring Cross-functional Alignment and Collaboration

    • Medical Affairs’ work with internal colleagues to ensure successful launch
    • Role of Medical Affairs group in cross-functional launch teams

    III: Adopting to Ongoing Changes in Medical Landscape

    • Change fronts for medical launch evolution
    • Change in Medical Affairs’ launch role within the last 3 years around data dissemination and communication
    • Change in Medical Affairs’ launch role within the last 3 years around medical education
    • Change in Medical Affairs’ launch role within the last 3 years around organizational support

    IV: Launch Timeline, Preparedness Metrics and Resourcing

    • Medical Affairs’ launch activities timeline
    • Total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for a product during each of the years in launch phase
    • Presence of a launch dashboard and information used with the dashboard
    • Percentage of total Medical Affairs launch investment allocated to each of the listed Medical Affairs activities during each time period
    • Percentage of total Medical Affairs launch FTEs allocated to each of the listed Medical Affairs activities

    V: Critical Success Factors and Major Pitfalls

    • Critical success factors for Medical Affairs launch
    • Areas where advanced team planning is key
    • Six critical areas for successful Medical Affairs launch readiness
    • Major pitfalls for Medical Affairs during launch
    • Six major challenge areas for Medical Affairs during launch
    VI: Digital Influence on Launch Processes and Launch Tool Deployment

    • Change in digital technology utilization among Medical Affairs groups during product launches post the pandemic
    • Level of influence on current and future launch processes with the use of digital technology
    • Digital tools deployed by Medical Affairs during the product launch cycle
    • Impact of top three digital activities that Medical leads
    • Impact of digital activities and programs used to support a successful pharma product launch
    • Top three digital tools that can bring success to Medical Affairs and product launch activities
    • Fast-growing digital tools that are impacting Medicals’ launch strategy
    • Example of a valuable digital tool that supports launch activities

    VII: Participant Demographics

    • Geographic responsibility of benchmark participants
    • Therapeutic areas that participating Medical Affairs organizations are responsible for

    VIII: Detailed Benchmark Study Data

    • Role served by Medical Affairs in product launch
    • Medical Affairs launch role effectiveness
    • Role served by Medical Affairs in planning, research, and education activities
    • Role served by Medical Affairs in data dissemination and organizational support activities
    • Role served by Medical Affairs in research activities
    • Role served by Medical Affairs in education and data dissemination support activities
    • Role served by Medical Affairs in organizational support activities
    • Medical Affairs launch activity involvement timeline - Evidence generation and field-based medical activities
    • Medical Affairs launch activity involvement timeline - Medical information and regulatory activities
    • Medical Affairs launch activity involvement timeline - HEOR activities and communications
    • Medical Affairs launch activity involvement timeline - Independent medical education and external engagement activities